Intermittent administration of betalactam-antibiotics for treatment of severe infection in hemodialysis patients

European Journal of Medical Research

Volumn 10, Issue 4, 2005, Pages 140-144

  Meyer, B ^a   Guttmann, C ^a   Dittrich, E ^a   Schmaldienst, S ^a   Thalhammer, Florian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Betalactams; Hemodialysis; Infection; Intermittent administration; Nephropharmacology

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; CEFEPIME; CEFPIROME; CEFTAZIDIME; FLUCONAZOLE; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; AMBULATORY CARE; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HUMAN; MALE; MENTAL DISEASE; MONOTHERAPY; MORBIDITY; MORTALITY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; C-REACTIVE PROTEIN; CEFTAZIDIME; CEPHALOSPORINS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; PIPERACILLIN; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 17844399577     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Yeun JY, Levine RA, Mantadilok V et al. (2000) C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35: 469-76
2. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wannet C (1999) Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648-658
3. Berman SJ, Johnson EW, Nakatsu C, Alkan M, Chen R, LeDuc J (2004) Burden of Infection in patients with end-stage renal disease requiring long-term dialysis. Clin Infect Dis 39: 1747-53
4. Ryan SV, Calligaro KD, Dougherty MJ (2004) Management of hemodialysis access infections. Semin Vasc Surg 17: 40-44
5. Schmaldienst S, Hörl WH (1996) Bacterial infections during immunosuppression - immunosuppressive agents interfere not only with immunoresponse, but also with polymorphonuclear cell function. Nephrol Dial Transplant 11: 1243-45
6. Haag-Weber M, Hörl WH (1993) Uremia and infection: mechanisms of impaired cellular host defense. Nephron 63: 125-31
7. Hoen P, Paul-Dauphin A, Hestin D et al. (1998) EPIRACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 9: 869-76
8. Kessler M, Hoen B, Mayeux D et al. (1993) Bacteremia in patients on chronic hemodialysis. Nephron 64: 95-100
9. Maraj S, Jacobs LE, Maraj R, Kotler MN (2004) Bacteremia and infective endocarditis in patients on hemodialysis. Am J Med Sci 327: 242-49
10. Powe NR, Jaar B, Furth SL et al. (1999) Septicemia in dialysis patients: incidence, risk factors, and prognosis. Kidney Int 55: 1081-90
11. Nassar GM, Ayus JC (2001) Infectious complications of the hemodialysis access. Kidney Int 60: 1-13
12. Tokars JI, Light P, Anderson J et al. (2001) A prospective study of vascular access infections at seven outpatient hemodialysis centers. Am J Kidney Dis 37: 1232-40
13. Sowinski KM, Mueller BA, Grabe DW et al. (2001) Cefazolin Dialytic Clearance by High-Efficiency and High-Flux Hemodialyzers. Am J Kidney Dis 37: 766-776
14. Schmaldienst S, Traunmüller F, Burgmann H et al. (2000) Multiple-dose pharmacokinetics of cefepime in long-term hemodialysis with high-flux membranes. Eur J Clin Pharmacol 56: 61-4
15. Thalhammer F, Schmaldienst S, El-Menyawi I et al. (1996) Multiple-dose pharmacokinetics of cefpirome in long-term hemodialysis with high-flux membranes. Clin Pharmacol Ther 60: 645-50
16. Thalhammer F, Rosenkranz AR, Burgmann H et al. (1997) Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes. Wien Klin Wochenschr 109: 362-5
17. Czock D, Keller F, Thalhammer F (2003) Medikamentendosierung bei kontinuierlicher Hämofiltration. Intensivmed 40: 269-381
18. Dasgupta MK (2002) Biofilms and infection in dialysis patients. Semin Dial 15: 338-46
19. Maki DG, Jarrett F, Sarafin HW (1977) A semiquantitative culture method for identification of catheter-related infection in the burn patient. J Surg Res 22: 513-20
20. Iseki K, Tozawa M, Yoshi S et al. (1999) Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 14: 1956-60
21. Owen WF, Lowrie EG (1998) C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 54: 627-36
22. Golper TA, Schulman G, D'Agata EM (2000) Indications for vancomycin in dialysis patients. Semin Dial 13: 389-92
23. Atta MG, Eustace JA, Song X, Perl TM, Scheel PJ (2001) Outpatient vancomycin use and vancomycin-resistant enterococci colonization in maintenance dialysis patients. Kidney Int 59: 718-24
24. Berns JS (2003) Infection with Antimicrobial-resistant microorganisms in dialysis patients. Semin Dial 16: 30-37
25. Lentino JR, Baddour LM, Wray M, Wong ES, Yu VL (2000) Clinical and epidemiologic studies: Staphylococcus aureus and other bacteremias in hemodialysis patients: Antibiotic therapy and surgical removal of access site. Infection 28: 355-60
26. Wong KM, Chan YH, Cheung CY et al. (2001) Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis. Am J Kidney Dis 38: 127-31
27. Banyai M, Thalhammer F, El-Menyawi I, Heinz G, Traunmüller F, Siostrzonek P (2000) Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval. Clin Pharmacol Ther 67: 368-72
28. Gabutti L, Taminelli-Beltramelli L, Marone C (1997) Clearance of ceftriaxone during hemodialysis using cuprophane, haemophane and polysulfone dialyzers. Eur J Clin Pharmacol 53: 123-26
29. Veys N, Lameire N, Malerczyk V, Lehr KH, Rosenkranz B, Ringoir S (1993) Single-dose pharmacokinetics of cefpirome in patients receiving hemodialysis and in patients treated by continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 54: 395-401
30. Burgess DS, Hastings RW, Hardin TC (2000) Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther 22: 66-75
31. Thalhammer F, Traunmüller F, El Menyawi I et al. (1999) Continuous versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 43: 523-27
32. Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Guay DR, Pittmann KA (1990) Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther 48: 268-276